Author

M. Sibai

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:cell-cell communication· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

B. A. Pinsky· 2 shared A. Bernat· 1 shared A. Creanga· 1 shared A. Derrien-Colemyn· 1 shared A. Fortian· 1 shared A. Lazar· 1 shared A. Narayanan· 1 shared A. Pegu· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

B. A. Pinsky

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The spatial landscape of Cancer Hallmarks reveals patterns of tumor ecology

M. Sibai, S. Cervilla, D. Grases, E. Musulen, R. Lazcano, C.-K. Mo, V. Davalos, A. Fortian, M. Romeo, A. Bernat, C. Tokheim, E. Grande, F. Real, J. Barretina, A. Lazar, , E. Porta-Pardo

The paper uses spatial transcriptomics to analyze Cancer Hallmarks in 63 tumors, revealing spatial patterns of hallmark activity and interdependencies between cancer and tumor microenvironment.

bioRxiv · Jun 18, 2022Cancer Biology

Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen

S. Saul, M. Karim, P.-T. Huang, L. Ghita, W. Chiu, S. Kumar, N. Bhalla, P. Leyssen, C. A. Cohen, K. E. Huie, C. Tindle, M. Sibai, B. A. Pinsky, S. Das, P. Ghosh, , S. Einav

This study identifies lapatinib, an ErbB inhibitor, as a broad-spectrum antiviral that suppresses SARS-CoV-2 and VEEV replication, inflammation, and lung injury through ErbB-mediated mechanisms.

bioRxiv · May 15, 2021Microbiology

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant

V.-V. Edara, L. Lai, M. Sahoo, K. Floyd, M. Sibai, D. Solis, M. W. Flowers, L. Hussaini, C. R. Ciric, S. Bechnack, K. Stephens, E. B. Mokhtari, P. Mudvari, A. Creanga, A. Pegu, , M. Suthar

This study assesses neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant in convalescent and vaccinated individuals, finding it is 6.8-fold more resistant but still neutralizable.

bioRxiv · May 9, 2021 · PreprintImmunology